Trisha Shetty (Editor)

5 HT3 receptor

Updated on
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
5-HT3 receptor Molecular Psychiatry Antipsychotic drugs antagonise human

Similar  5 HT1 receptor, 5 HT4 receptor, 5 HT5A receptor

The 5 ht3 receptors and antiemetics part 1

The 5-HT3 receptor belongs to the Cys-loop superfamily of ligand-gated ion channels (LGICs) and therefore differs structurally and functionally from all other 5-HT receptors (5-hydroxytryptamine, or serotonin) receptors which are G protein-coupled receptors. This ion channel is cation-selective and mediates neuronal depolarization and excitation within the central and peripheral nervous systems. As with other ligand gated ion channels, the 5-HT3 receptor consists of five subunits arranged around a central ion conducting pore, which is permeable to sodium (Na), potassium (K), and calcium (Ca) ions. Binding of the neurotransmitter 5-hydroxytryptamine (serotonin) to the 5-HT3 receptor opens the channel, which, in turn, leads to an excitatory response in neurons. The rapidly activating, desensitizing, inward current is predominantly carried by sodium and potassium ions. 5-HT3 receptors have a negligible permeability to anions. They are most closely related by homology to the nicotinic acetylcholine receptor.


5-HT3 receptor Xray structure of the mouse serotonin 5HT3 receptor Nature

The 5 ht3 receptors part 1


5-HT3 receptor Recent developments in 5HT3 receptor pharmacology Trends in

The 5-HT3 receptor differs markedly in structure and mechanism from the other 5-HT receptor subtypes, which are all G-protein-coupled. A functional channel may be composed of five identical 5-HT3A subunits (homopentameric) or a mixture of 5-HT3A and one of the other four 5-HT3B, 5-HT3C, 5-HT3D, or 5-HT3E subunits (heteropentameric). It appears that only the 5-HT3A subunits form functional homopentameric channels. All other subunit subtypes must heteropentamerize with 5-HT3A subunits to form functional channels. Additionally, there has not currently been any pharmacological difference found between the heteromeric 5-HT3AC, 5-HT3AD, 5-HT3AE, and the homomeric 5-HT3A receptor.

5-HT3 receptor 5HT3 receptor signaling pathways in neurons The 5HT3R as

The subunits surround a central ion channel in a pseudo-symmetric manner (Fig.1). Each subunit comprises an extracellular N-terminal domain which comprises the orthosteric ligand-binding site; a transmembrane domain consisting of four interconnected alpha helices (M1-M4), with the extracellular M2-M3 loop involved in the gating mechanism; a large cytoplasmic domain between M3 and M4 involved in receptor trafficking and regulation; and a short extracellular C-terminus (Fig.1). Whereas extracellular domain is the site of action of agonists and competitive antagonists, the transmembrane domain contains the central ion pore, receptor gate, and principle selectivity filter that allows ions to cross the cell membrane.


5-HT3 receptor Frontiers The serotonin 5HT3 receptor a novel neurodevelopmental

The 5-HT3 receptor gene is located on human chromosomal region 11q23.1-q23.2. It is similar in structure to the mouse gene which has 9 exons and is spread over ~13 kb. Interestingly, four of its introns are exactly in the same position as the introns in the homologous α7-Acetylcholine receptor gene, clearly proving their evolutionary relationship. Genes that code for the subunits of the 5-HT3 receptor have been identified. HTR3A and HTR3B for the 5-HT3A and 5-HT3B subunits and in addition HTR3C, HTR3D and HTR3E genes encoding 5-HT3C, 5-HT3D and 5-HT3E subunits. The latter three tend to show peripherally restricted pattern of expression, with high levels in the gut. In human duodenum and stomach, for example, 5-HT3C and 5-HT3E mRNA might be greater than for 5-HT3A and 5-HT3B. There is some evidence to suggest that the 5-HT3 receptor subunits are an important contribution to the effectiveness of these compounds. In patients treated with chemotherapeutic drugs, certain polymorphism of the HTR3B gene could predict successful antiemetic treatment. This could indicate that the 5-HT3B receptor subunit could be used as biomarker of antiemetic drug efficacy. HTR3C and HTR3E do not seem to form functional homomeric channels, but when co-expressed with HTR3A they form heteromeric complex with decreased or increased 5-HT efficacies. The pathophysiological role for these additional subunits has yet to be identified.

Tissue distribution

5-HT3 receptor httpsiytimgcomviVjjztToHmwhqdefaultjpg

The 5-HT3 receptor is expressed throughout the central and peripheral nervous systems and mediates a variety of physiological functions. On a cellular level, it has been shown that postsynaptic 5-HT3 receptors mediate fast excitatory synaptic transmission in rat neocortical interneurons, amygdala, and hippocampus, and in ferret visual cortex. 5-HT3 receptors are also present on presynaptic nerve terminals. There is some evidence for a role in modulation of neurotransmitter release, but evidence is inconclusive.


When the receptor is activated to open the ion channel by agonists, the following effects are observed:

  • CNS: nausea and vomiting center in brain stem, anxiety, seizure propensity
  • PNS: neuronal excitation (in autonomic, nociceptive neurons), emesis
  • Agonists

    Agonists for the receptor include:

  • 2-methyl-5-HT
  • Alpha-Methyltryptamine
  • Bufotenin
  • Chlorophenylbiguanide
  • Ethanol
  • Ibogaine
  • Phenylbiguanide
  • Quipazine
  • RS-56812: Potent and selective 5-HT3 partial agonist, 1000x selectivity over other serotonin receptors
  • SR-57227
  • Varenicline
  • YM-31636
  • Antagonists

    Antagonists for the receptor (sorted by their respective therapeutic application) include:

  • Antiemetics
  • AS-8112
  • Granisetron
  • Ondansetron
  • Tropisetron
  • Gastroprokinetics
  • Alosetron
  • Batanopride
  • Metoclopramide (high doses)
  • Renzapride
  • Zacopride
  • M1, the major active metabolite of mosapride
  • Antidepressants
  • Mianserin
  • Mirtazapine
  • Vortioxetine
  • Antipsychotics
  • Clozapine
  • Olanzapine
  • Quetiapine
  • Others
  • 3-Tropanyl Indole-3-carboxylate
  • Lamotrigine (epilepsy and bipolar disorder)
  • Memantine (Alzheimer's disease medication)
  • Menthol
  • Thujone
  • Positive Allosteric Modulators

    These agents are not agonists at the receptor, but increase the affinity or efficacy of the receptors for an agonist:

  • 5-chloroindole
  • Discovery

    Identification of the 5-HT3 receptor did not take place until 1986 because of a lack of selective pharmacological tool. However, with the discovery that the 5-HT3 receptor plays a prominent role in chemotherapy- and radiotherapy-induced vomiting, and the concomitant development of selective 5-HT3 receptor antagonists to suppress these side effects aroused intense interest from the pharmaceutical industry and therefore the identification of 5-HT3 receptors in cell lines and native tissues quickly followed.


    5-HT3 receptor Wikipedia

    Similar Topics
    5 HT1 receptor
    5 HT4 receptor
    5 HT5A receptor